Literature DB >> 8388462

Agonist and antagonist profiles of [D-Ala2,Glu4]deltorphin and its [Cys4]- and [Ser4]-substituted derivatives: further evidence of opioid delta receptor multiplicity.

P J Horan1, K D Wild, A Misicka, A Lipkowski, R C Haaseth, V J Hruby, S J Weber, T P Davis, H I Yamamura, F Porreca.   

Abstract

Pharmacological evidence has suggested the presence of two supraspinal opioid delta receptor subtypes in the mouse, termed delta-1 and delta-2. [D-Pen2,D-Pen5]enkephalin (DPDPE) is thought to be primarily an agonist at the opioid delta-1 subtype, whereas H2N-Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 ([D-Ala2,Glu4]deltorphin) is a selective agonist at the delta-2 subtype. Based on previous reports suggesting that a receptor sulfhydryl group may be critical for ligand binding to the opioid delta receptor, the present investigation has attempted to discover whether this concept extends to the opioid delta-2 receptor. For this purpose, a cysteine-substituted deltorphin was synthesized and the potential agonist and antagonist properties of this compound, H2N-Tyr-D-Ala-Phe-Cys-Val-Val-Gly-NH2 ([D-Ala2,Cys4]deltorphin), were evaluated in an antinociceptive assay after i.c.v. administration to mice and stability in mouse brain was determined. As a control a serine-substituted deltorphin was also prepared and the potential agonist and antagonist properties of this compound, H2N-Tyr-D-Ala-Phe-Ser-Val-Val-Gly-NH2 ([D-Ala2,Ser4]deltorphin), as well as those of the parent deltorphin, [D-Ala2,Glu4]deltorphin, were evaluated. Acutely, [D-Ala2,Cys4]deltorphin, [D-Ala2,Ser4]deltorphin and [D-Ala2,Glu4]deltorphin each produced dose-related antinociceptive effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388462

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  1 in total

1.  Development of mu/delta opioid ligands: enkephalin analogues containing 4-anilidopiperidine moiety.

Authors:  YeonSun Lee; Ravil Petrov; Vinod Kulkarni; Byoung J Min; Shou-Wu Ma; Peg Davis; Janice Oyarzo; Todd Vanderah; Josephine Lai; Frank Porreca; Ruben Vardanyan; Victor J Hruby
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.